#COVID VARIANT

[spooniestrong]

[intersectionalpraxis]

Researchers discovered this new variant via wastewater. They reported that it already makes up 1/4 of US Covid cases.

Symptoms include: fever or chills, fatigue, "brain fog," difficulty breathing, muscle aches, new loss of taste or smell.

All of this information I stated above can be found here:

I will definitely be updating about this new variant as more information is made available to the public.

[gumjrop]

The Weather

In the US, 41 out of 54 states and territories are at high or very high COVID wastewater levels as of 1/18/2024. Ten states and territories have no data available. It’s important to note that levels of “moderate,” “low,” or “minimal” do not necessarily indicate a low risk of COVID exposure in our daily lives. Viral spread is still ongoing even if at lower levels, and precautions are warranted to protect ourselves and others.

Looking at the CDC’s national and regional wastewater data over time, we continue to see “Very High” levels nationally. It’s important to note that the last two weeks are provisional data, indicated by a gray shaded area on the graph, meaning that those values can change as additional wastewater sites report data. 

Although wastewater data does not provide the same level of detail as previous PCR-based testing data, wastewater monitoring is an important ongoing resource to inform us about the current COVID situation. While the provisional data tentatively shows a downward trend this week, time will tell whether this is a true decrease in the final data. A downward trend does not mean continued decreases are guaranteed or that protections should be relaxed. Multilayered protections help drive COVID spread lower, and relaxing protections can lead to a resurgence of viral spread.

Visit the CDC’s State and Territory Trends page to see available wastewater testing near you, including the number of wastewater sites reporting. Write your elected officials to let them know you want to keep and expand wastewater testing in your area and nationally.

Wins

In November 2023, the CDC’s Healthcare Infection Control Practices Advisory Committee (HICPAC) passed a series of draft proposals that will further weaken already insufficient protocols employed within healthcare settings. HICPAC refuses to reckon with the airborne nature of infectious diseases such as SARS-CoV-2, and does not propose crucial measures such as universal masking with well-fitted respirators, isolation periods, and ventilation. The People’s CDC has penned a letter to the ACLU alerting them of HICPAC’s irresponsible decisions, and the ramifications associated with them. We hope that by working together with the ACLU, we can implement public advocacy and legal actions in order to tackle this critical issue.

You can read the full letter here.

Johns Hopkins reinstated healthcare masking on 1/12/2024, in response to high respiratory virus levels. As with many other healthcare systems and public health departments that have restored healthcare masking when facing public pressure, we hope that universal masking can become a standard of care rather than a short term response to a surge. See “Take Action” below for more information.

Variants

JN.1, now the most prominent variant in the United States, is estimated to account for 85.7% of circulating variants by 1/20/2024. HV.1 is expected to drop to 5.3%, and all other variants are estimated to make up less than 2% each. Although ongoing viral spread allows opportunities for new variants to emerge, the latest 2023-2024 COVID vaccine boosters, COVID tests, and COVID treatments are still expected to be effective for JN.1.

Current updated booster uptake is low (as of January 19, 2024, the CDC reports that only 21.5% of adults and 11% of children have received it). It is not too late to get the updated booster, and to protect yourself against the latest variant! 

Hospitalizations

In the most recent week (ending January 13, 2024), we see a slight downward trend in new hospital admissions, currently at 32,861. We see a similar slight downtick in currently hospitalized patients with COVID , at 27,879. This most recent week shows a slight decrease in hospitalizations, although it is too soon to say whether hospitalizations for the current surge have passed their peak. Hospitals continue to be overwhelmed. The data also lacks information on hospital-acquired infections. We urge you to continue taking stringent precautions, such as donning a well-fitting respirator (e.g., N95, KN95) in all indoor spaces–and especially in healthcare settings.

Long COVID

Amid ongoing advocacy by Long COVID groups, the US Senate Committee on Health, Education, Labor, and Pensions (HELP) held a committee hearing on “Addressing Long COVID: Advancing Research and Improving Patient Care.” The hearing included testimony from three Long COVID patients and four Long COVID physicians and researchers, bringing much-needed attention to the urgent need for funding for Long COVID research and treatments, and to the need for improved access to care for Long COVID patients. We recognize the community care modeled by some of the panelists and attendees who wore masks for the hearing, and we wish the senators on the committee would mask up as well. 

Take Action

Write your elected officials to let them know that Long COVID impacts all of us, and that we need ongoing support for Long COVID research and clinical care. Ask Senators to support bill S.2560, the Long COVID Support Act. Ask Representatives to support bills HR.1114 (Long COVID RECOVERY NOW Act) and HR.3258 (TREAT Long COVID Act).

Although some healthcare settings have reinstated masking in response to high COVID levels along with high respiratory virus activity, ongoing pressure is needed to restore, keep, and expand masking broadly. Use our letter template and toolkit to call or write your elected officials in support of healthcare masking.

Want to do more to support healthcare masking? Consider starting, sharing, or joining a local campaign. Check out work in Illinois, Maryland, and Wisconsin, just to name a few. Also, sign and share our letter to the ACLU asking them to join us in supporting safe and equitable access to healthcare. Sign on is open until 2/1/2024. 

[arctic-hands]

Out of curiosity, are there any variants going around where there are no respiratory symptoms but there is heavy fatigue? neither theta and I have any resp symptoms or fevers or anything, but we've been so dead tired that nothing's getting done. We're both chronically ill and disabled, but it's weird for both of us to be this tired and flaring at the same time

[kp777]

No paywall.

[aliensexdream]

Rating COVID variants on tripreport:

PIROLA (BA.2.86) - This one comes in at a respectable second place only to the unbelievable oiginal Wild Type. Severe, intermittent neurological impacts. Fading in and out, a creeper type high. Copious phlegm, various secretions. Stomach pain. Body wrecked. Could return at any moment. Never turn your back on this one. 8/10

OMICRON - Respectable choice for first timers, more of a body high. You're awake, dreaming only sometimes. Still on planet earth. 5/10

DELTA - Feels similar to playing Bloody Mary in the bathroom as a kid. Only a flesh wound. Childs play. 2/10

WILD TYPE - Do not pass go. Do not collect $200. This shit will have you crawling towards the light at the end of the tunnel and praying for a mercy killing. 10/10

[dddemigirl]

There’s a new covid surge. Immunocompromised people are encouraged to mask up. Some schools are going remote again. I just got my booster shot and I’m not afraid of wearing a little face covering. I’m already home most days. This won’t be much of a change for me.

[nuadox]

FAQ on COVID-19 subvariant XBB.1.5

- By Sameer Elsayed , Western University , The Conversation -

Despite intensive public health efforts to grind the COVID-19 pandemic to a halt, the recent emergence of the highly transmissible, extensively drug-resistant and profoundly immune system-evading XBB.1.5 SARS-CoV-2 subvariant is putting the global community on edge.

What is XBB.1.5?

In the naming convention for SARS-CoV-2 lineages, the prefix “X” denotes a pedigree that arose through genetic recombination between two or more subvariants.

The XBB lineage emerged following natural co-infection of a human host with two Omicron subvariants, namely BA.2.10.1 and BA.2.75. It was first identified by public health authorities in India during summer 2022. XBB.1.5 is a direct descendent, or more accurately, the “fifth grandchild” of the original XBB subvariant.

Genetic lineage of COVID-19 subvariant XBB.1.5. (Sameer Elsayed), Author provided

How does XBB.1.5 differ from Omicron?

XBB.1.5 is one of many Omicron subvariants of concern that have appeared on the global pandemic scene since the onset of the first Omicron wave in November 2021. In contrast to other descendants of the original Omicron variant (known as B.1.1.529), XBB.1.5 is a mosaic subvariant that traces its roots to two Omicron subvariant lineages.

XBB.1.5 is arguably the most genetically rich and most transmissible SARS-CoV-2 Omicron subvariant yet.

Where is XBB.1.5 prevalent?

According to the World Health Organization, XBB.1.5 is circulating in at least 38 countries, with the highest prevalence in the United States, where it accounts for approximately 43 per cent of COVID-19 cases nationwide. Within the U.S., there is wide geographic variation in the proportion of cases caused by XBB.1.5, ranging from seven per cent in the Midwest to over 70 per cent in New England.

XBB.1.5 has also been officially reported by governmental agencies in Australia, Canada, the European Union, Japan, Kuwait, Russia, Singapore, South Africa and the United Kingdom. Real-time surveillance data reveals that XBB.1.5 is rapidly spreading across the globe and will likely become the next dominant subvariant.

XBB.1.5 has also been detected in municipal wastewater systems in the United States, Europe and other places.

How likely is XBB.1.5 to cause serious illness?

There is limited data about the ability of XBB.1.5 to cause serious illness. According to the World Health Organization, XBB.1.5 does not have any specific mutations that make it any more dangerous than its ancestral subvariants.

Nonetheless, XBB.1.5 is perceived as being equally capable of causing serious illness in elderly and immunocompromised persons compared to previous Omicron subvariants of concern.

Are current mRNA vaccines effective against XBB.1.5?

XBB.1.5 and XBB.1 are the Omicron subvariants with the greatest immune-evasive properties. Therefore, one of the most contentious issues surrounding XBB.1.5 relates to the degree of protection afforded by currently available mRNA vaccines, including the latest bivalent booster formulations.

Researchers from the University of Texas determined that first-generation and bivalent mRNA booster vaccines containing BA.5 result in lacklustre neutralizing antibody responses against XBB.1.5. A report (yet to be peer reviewed) from investigators at the Cleveland Clinic found that bivalent vaccines demonstrate only modest (30 per cent) effectiveness in otherwise healthy non-elderly people when the variants in the vaccine match those circulating in the community.

Furthermore, some experts believe the administration of bivalent boosters for the prevention of COVID-19 illness in otherwise healthy young individuals is not medically justified nor cost-effective.

In contrast, public health experts from Atlanta, Ga. and Stanford, Calif. reported that although the neutralizing antibody activity of bivalent booster vaccines against XBB.1.5 is 12 to 26 times less than antibody activity against the wild-type (original) SARS-CoV-2 virus, bivalent vaccines still perform better than monovalent vaccines against XBB.1.5.

However, investigators from Columbia University in New York found that neutralizing antibody levels following bivalent boosting were up to 155–fold lower against XBB.1.5 compared to levels against the wild-type virus following monovalent boosting.

This suggests that neither monovalent nor bivalent booster vaccines can be relied upon to provide adequate protection against XBB.1.5.

How can you protect yourself against XBB.1.5?

The rapid evolution of SARS-CoV-2 continues to pose a challenge for the management of COVID-19 illness using available preventive and therapeutic agents. Of note, all currently available monoclonal antibodies targeting the spike protein of SARS-CoV-2 are deemed to be ineffective against XBB.1.5.

Antiviral medicines such as remdesivir and Paxlovid may be considered for the treatment of eligible infected patients at high risk of progressing to severe disease.

Standard infection control precautions including indoor masking, social distancing and frequent handwashing are effective measures that can be employed for personal and population protection against XBB.1.5 and other subvariants of concern.

Although bivalent boosters may be considered for elderly, immunocompromised and other risk-averse individuals, their effectiveness in preventing COVID-19 illness due to XBB.1.5 remains uncertain.

Why is XBB.1.5 nicknamed ‘Kraken’?

Some scientists have coined unofficially-recognized nicknames for XBB.1.5 and other SARS-CoV-2 subvariants of concern, arguing that they are easier to remember than generic alphanumeric designations.

The ‘Kraken’ label for XBB.1.5 is currently in vogue on social media sites and news outlets, and the nicknames ‘Gryphon’ and ‘Hippogryph’ have been used to denote the ancestral subvariants XBB and XBB.1, respectively. Kraken refers to a mythological Scandinavian sea monster or giant squid, Gryphon (or Griffin) refers to a legendary creature that is a hybrid of an eagle and a lion, while Hippogryph (or Hippogriff) is a fictitious animal hybrid of a Gryphon and a horse.

Notwithstanding their potential utility as memory aids, the use of nicknames or acronyms in formal scientific discussions should be avoided.

Sameer Elsayed, Professor of Medicine, Pathology & Laboratory Medicine, and Epidemiology & Biostatistics, Western University

This article is republished from The Conversation under a Creative Commons license. Read the original article.

--

Read Also

Study: 30% of COVID patients develop ‘long COVID’

[publicacionesconverclick]

WHY ARE PEOPLE SUDDENLY GETTING COVID-19 THIS SUMMER? UNDERSTANDING THE INCREASE

by ads Converclick on June 26, 2024

Explore why COVID-19 cases are rising this summer and learn about the new FLiRT variants driving the increase. Discover how the Status™ COVID-19/Flu A&B test provides rapid, accurate diagnosis to manage and prevent respiratory illnesses effectively. Stay informed and protect your health.

[liberty1776]

The latest SARS-CoV-2 variant, JN.1, was first detected in the U.S. in September 2023. By mid-December, it accounted for about half of all COVID cases in the country,1 and calls to get the latest “updated” COVID shot resumed. Cases associated with this variant are also on the rise in the U.K., China and India.2 Turtles All The Way Do... Anonymous Best Price: $21.69 Buy New $22.38 (as of 06:13 UTC - Details) According to the U.S. Centers for Disease Control and Prevention, the rapid spread of JN.1 suggests it may be more transmissible and/or has greater immune-evading abilities:3 “JN.1 is similar … Continue reading →